CA-SCIENTIST.COM
1.4.2021 13:57:06 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading marketplace for life science research, announced today that it has partnered with Charles River , Certis Oncology and other leading oncology CROs to launch a Disease Model Finder that helps medical researchers use genetic, cellular and patient data to find the most appropriate research models for their preclinical development projects.
“Our proprietary model selection software uses multiple machine learning algorithms to help researchers sift through large amounts of data and identify in vitro and in vivo models for their research,” stated Javier Pineda, PhD, Data Scientist at Scientist.com. “Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.”
The Disease Model Finder brings together a wealth of data that can help scientists choose the right preclinical disease models. DNA sequencing data from CRO partners is uploaded and analyzed so that researchers can easily search for models based on the presence (or absence) of a mutated gene or by the up or down regulation of gene expression. Marketplace customers can then filter their search results based on cancer type, subtype and characteristics or patient information.
“Scientist.com’s new Disease Model Finder will enable pharma and biotech researchers to find and purchase the most appropriate Charles River models for their drug development programs,” said Melissa Schroeder, E-Commerce Manager at Charles River. “Having access to advanced data that better matches a patient-derived xenograft (PDX) model with a research program will enable optimal study design, ultimately saving time and money as clients race to get critical therapies to patients.”
At launch, the Disease Model Finder includes 650 PDX models provided by Charles River, Certis, XenTech , the Lab for Innovated Diagnosis and Experimental Therapeutics (LIDE) and others—a number that is projected to grow quickly as more CROs join the program. By 2022, the platform will include other model systems including organoids, cell-derived xenografts (CDX), syngeneic models, immunoncology models and patient-derived cell lines.
“With so many drugs failing in human clinical trials because they don’t work, it is imperative that we use more predictive preclinical models of disease,” stated Peter Ellman, Certis Oncology CEO. “By combining gene analysis, patient data and tissue profiling data, Scientist.com’s Disease Model Finder increases the odds that researchers are selecting the right Certis models for translational drug development.”
To learn more please visit https://www.scientist.com/disease-model-finder/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer8.10.2026 13:30:00 CEST | Press release
Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combinationArmenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance dataApprovals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastasesAgenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory path Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL), each approved for use in combination with the other for the treatment of adult patients with microsatell
NTT DOCOMO BUSINESS and Classiq Enter Strategic Business Partnership to Accelerate Enterprise Adoption of Quantum Computing8.10.2026 13:00:00 CEST | Press release
Combining Classiq’s quantum software development platform with NTT DOCOMO BUSINESS's real-world implementation expertise to accelerate enterprise quantum adoption NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) and Classiq Technologies G.K., the Japanese subsidiary of Classiq Technologies Ltd., today announced a memorandum of understanding establishing a strategic business partnership aimed at accelerating enterprise adoption of quantum computing1 in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007985427/en/ NTT DOCOMO BUSINESS and Classiq logos Under the partnership, NTT DOCOMO BUSINESS will propose and sell the Classiq quantum software development platform and work with Classiq to help enterprises identify, develop and validate quantum computing use cases. Classiq will provide the platform, along with expertise and technical support related to quantum algorithms and quantum software technolo
Movado Group, Inc. Enters Into Agreement to Sell Majority Interest in EBEL8.10.2026 12:45:00 CEST | Press release
Movado Group, Inc. (NYSE: MOV) today announced that it has entered into a binding agreement to sell a 95% interest in its EBEL brand for $66.5 million to a strategic buyer group led by Montres Journe SA (“Montres Journe”), a Geneva-based luxury watch manufacturer, with the participation of Chanel (“Chanel”), the luxury house, and Pierre Jacques, a renowned figure in the Swiss watch industry, who will serve as Chief Executive Officer of EBEL. The transaction is subject to customary adjustments and closing conditions with Movado Group retaining a 5% interest in the business. Founded in Switzerland in 1911, EBEL is a premium luxury watch brand known for its distinctive design, craftsmanship and rich heritage. This strategic sale allows Movado Group to sharpen its focus on its core accessible luxury and fashion watch and jewelry portfolio, while providing EBEL with a new ownership platform specifically positioned to support the brand’s long-term development. With the expertise and capital
NIQ Reaches Key Milestone in Acquisition of The U Group, Strengthening Trusted Intelligence and The Full View™8.10.2026 12:45:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia), has exceeded the 90% shareholder acceptance threshold under its off-market takeover bid for The U Group & Co Limited (The U Group), an Australian-based company specializing in consumer participation, receipt intelligence, and AI-powered data processing capabilities. Achieving the acceptance threshold represents a significant milestone in the transaction process and enables NIQ Australia to proceed with the compulsory acquisition of the remaining shares in The U Group in accordance with applicable Australian law. Building on a successful five-year partnership, the transaction strengthens NIQ's trusted intelligence foundation and advances its strategy to deliver the industry's most complete understanding of consumer buying behavior. By bringing together NIQ's measurement, analytics, and consumer intelligence capabilities with The U Group's consumer partici
Network X 2026 Brings Europe’s Telecom Leaders Together in Vienna to Define the Future of Connectivity8.10.2026 12:42:00 CEST | Press release
A1 Group, Swisscom, Orange, Deutsche Telekom, Vodafone, Drei Austria, 4iG, Kyivstar and other industry leaders headline telecoms premier event Network X 2026 unites the telecommunications industry’s most influential executives and technology leaders at VIECON Vienna from 13-15 October, with a high-powered Headliners programme focused on the forces reshaping the future of connectivity. Across three days, CEOs, CTOs, technology chiefs, regulators and industry experts from leading operators and technology organisations will examine how artificial intelligence, network sovereignty, broadband networks, 6G, cloud, infrastructure investment and new business models are changing the role of the telecom operator. The programme features senior executives from A1 Group, Swisscom, Drei Austria, A1 Austria, Orange, Deutsche Telekom, Vodafone Group, Kyivstar, 4iG Telecommunications Holding, Yettel Bulgaria, Play Poland, Orange Slovensko, NGMN Alliance and other major players across the global connect
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom